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We firstly report a patient who presented with severe complications after infection with
influenza A(H1N1) pdm2009, more than 1 year after recovery from severe H7N9 virus
infections. The population of patients who recovered from severe H7N9 infections might
be at a higher risk to suffer severe complications after seasonal influenza infections, and
they should be included in the high-risk populations recommended to receive seasonal
influenza vaccination.
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BACKGROUND
Since the emergence of human infections with avian influenza A (H7N9) virus in February 2013,
China has experienced four epidemic waves of this virus. Due to its co-circulation with influenza
A (H1N1) pdm09 (pH1N1), seasonal influenza A (H3N2 and H1N1), and influenza B viruses in
China, human co-infections with the avian H7N9 virus and these human influenza viruses have
been reported (Zhu et al., 2013; Li et al., 2014; Zhang et al., 2015). Most H7N9 patients had severe
symptoms during hospitalization and their pulmonary functions were seriously damaged, which
might have increased their susceptibility to subsequent viral infections including human seasonal
influenza viruses after their recovery from the H7N9 infection. Here, we report a case of pH1N1
virus infection who had survived from H7N9 infection about 1 year and 3 months ago.
CASE REPORT
On April 20, 2014, a 66-year-old retired man, who had a history of hypertension for over 20 years,
presented influenza-like-illness (ILI) symptoms with fever (38◦C), cough, and expectoration
sputum. According to the epidemiological investigation, 5 days before symptoms presentation
the patient visited a local live poultry market and purchased one pigeon. On April 25, he sought
medical care at community clinic when his symptoms were getting worse, where he was diagnosed
of left lower lobe pneumonia. Because of his severe conditions, he was transferred to the respiratory
department of a city level hospital on the same day and was diagnosed of left pneumonia and
chronic bronchitis. The admission assessment of vital signs revealed a temperature of 39◦C, a
pulse of 101 beats per minute, a blood pressure of 130/80 mmHg, a respirations rate of 22
breaths per minute, a saturation of peripheral oxygen (SpO2) of 99.4%, a pressures of oxygen
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TABLE 1 | Clinical characteristics of patient with confirmed H7N9 and
pH1N1 infection on hospital admission.
Characteristic H7N9 infection pH1N1 infection
Age (years) 66
Sex Male
Occupation Retired
Type of exposure Visited live poultry
market and
purchased one
pigeon
n/a
Underlying medical disorders Hypertension Hypertension
Smoking Yes No
Influenza vaccination No No
Onset of illness 20 April 2014 25 December 2015
Date of hospital admission 25 April 2014 27 December 2015
Date of hospital discharge 22 August 2014 4 January 2016
Signs of illness Fever, cough, and
expectoration
sputum
Fever, cough, and
sore throat
Temperature (◦C) 39.0 38.0
White blood count ( × 109/L) 3.7 11.3
Neutrophils ( × 109/L) 2.49 63%
Lymphocytes ( × 109/L) 0.796 2.39∗
Platelets ( × 109/L) 147 195∗
C reactive protein (mg/L) 70 9
PaCO2 (mm Hg) 26.1 32.5
PaO2 (mm Hg) 135 92
Saturation of peripheral
oxygen (%)
99.4 n/a
Chest radiography Pneumonia Pneumonia
Mechanical ventilation Yes No
Oseltamivir treatment Yes Yes
Oxygen treatment Yes Yes
Outcome Recovery Recovery
n/a, not applicable. ∗The data on hospital admission was not applicable and
showed the available data on 28 December 2015.
(PaO2) of 135 mmHg, and a carbon dioxide (PaCO2) of
26.1 mmHg (Table 1). Routine laboratory testing revealed
a white cell count (WBC) of 3.7 × 109/L with 59.8%
neutrophils and 70mg/L C reactive protein (CRP; Table 1).
Computed tomography (CT) of the chest showed left upper
lobe pneumonia, lower lobe interstitial fibrosis, lower lobe
predominant emphysema, and mediastinal lymph nodes
(Figure 1A). On the following day, the patient developed high
fever (40.1◦C) with cough and expectoration sputum. He was
prescribed with ceftriaxone tazobactam and levofloxacin after his
hospital admission. When these antibiotics turned out ineffective,
he was then treated with imipenem cilastatin, vancomycin, and
meropenem. However, due to the poor treatment effectiveness
of these medicine and continuous deterioration of the disease
condition, he was sent to the intensive care unit on May 7,
and given oxygen nasal cannula and mechanical ventilation
successively as well as oseltamivir 75 mg twice daily. On May
14, his nasal and throat samples were collected and were tested
positive for H7N9 virus using real time reverse transcription
PCR (rRT-PCR). After the confirmative diagnosis, he continued
FIGURE 1 | Computed tomography (CT) images of the patient. (A) and
(B) show CT images of the patient infected with H7N9 virus on 25 April 2014
and of the patient infected with pH1N1 virus on 27 December 2015,
respectively. Left and right CT images are lung and mediastinal window,
respectively.
to receive oseltamivir 75 mg twice daily with imipenem and
moxifloxacin to help alleviate symptoms during May 15–26. On
August 22, he recovered from the disease and was discharged
from the hospital. Figure 2 summarizes the timeline of the events
mentioned above.
On December 25, 2015, 1 year and 3 months after his
infection with the avian influenza A(H7N9) virus, he presented
ILI symptoms again, with fever (38◦C), cough, and sore throat.
On December 27, he was admitted to the same city level
hospital and was diagnosed of severe pneumonia. On admission,
the patient had a temperature of 36.3◦C, a pulse of 77 beats
per minute, a blood pressure of 120/70 mmHg, a respirations
rate of 20 breaths per minute, a PaO2 of 92 mmHg, and a
PaCO2 of 32.5 mmHg (Table 1). Routine blood testing identified
a WBC of 11.3 × 109/L with 63% neutrophils and 9mg/L
CRP (Table 1). CT of the chest showed pulmonary interstitial
fibrosis with infection (Figure 1B). He was prescribed with
cefotiam, xiyanping (Chinese medicine for anti-virus infection),
doxofylline, and ambroxol as well as given oxygen nasal cannula.
On December 29, 2015, the local municipal Center for Disease
Control and Prevention was notified of the patient with severe
pneumonia. Because of his historical infection with avian
influenza A(H7N9) virus, an epidemiological investigation was
immediately conducted on December 30, and two throat samples
were collected and tested for avian influenza virus subtypes
(H7N9, H5N1, and H9N2) and human seasonal influenza
viruses (pH1N1 and seasonal H1 and H3) using rRT-PCR.
Both samples were positive for influenza A virus (Ct = 32.36)
and pH1N1 virus (Ct values are 31.15 for H1 and 32.35 for
N1), but negative for H7N9 or other subtypes of influenza
virus. After the confirmation of pH1N1 virus infection, his
treatment with prescribed drugs continued. On January 4, 2016,
he recovered from the disease and was discharged from the
hospital (Figure 2).
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FIGURE 2 | Timeline of events the patient associated with H7N9 and pH1N1 viruses infections in Wuxi, Jiangsu Province, China. rRT-PCR, real time
reverse transcriptase-polymerase chain reaction; ICU, intensive care unit.
HEMAGGLUTINATION INHIBITION
ASSAY
The serum hemagglutination inhibition (HAI) antibodies against
the H7N9 and pH1N1 were measured as previously described
(World Health Organization, 2013). The HAI titers against the
H7N9 virus (A/Jiangsu/Wuxi/04/2013) were 1:40 and 1:1280
in serum samples collected on May 15 and June 16 of
2014, respectively. The HAI titer against the pH1N1 virus
(A/California/07/2009) was 1:1280 in the convalescent serum
samples collected on January 25, 2016. To determine whether
the patient had HAI antibodies against the H7N9 virus more
than 1 year after his recovery, we tested the convalescent serum
for H7N9 virus and found the patient had a low HAI titer
of 1:10.
DISCUSSION
To our knowledge, this is the first report of a survivor of
the avian influenza H7N9 infection who were infected with
the human influenza pH1N1 virus after his recovery from the
disease. A previous study found that H7N9-infected patients
had rapidly developed robust antibody responses in 10–14 days
after symptom onset (Zhang et al., 2013). Our result also
showed a rapidly elicited robust antibody response after the
infection, but the antibody response became very weak against
H7N9 virus more than 1 year later. Whether the protective
antibody response decay substantially after 1 year or so in
general need further investigation in more survivors, and there
is likely heterogeneity across the population. Several studies
have shown that memory T cells and broadly neutralizing
antibodies induced by human seasonal influenza viruses may
provide some cross-protection against the avian H7N9 virus
(van de Sandt et al., 2014; Henry Dunand et al., 2015;
Richards et al., 2015). It is yet unclear whether previous
exposure to the avian H7N9 virus cross-protects against human
seasonal influenza viruses. Severe infection with avian influenza
viruses are known to be associated with delayed immune
recovery and impaired lung function (Chen et al., 2016). These
consequences may not have increased the susceptibility of
the patients who recovered from H7N9 to seasonal influenza
infection if subsequent infection occur. It is well known that
most people who get influenza will have mild illness and
will recover in a few days to less than 2 weeks. However,
some people, including young children, adults aged 65 years
and older, pregnant women, and people with chronic medical
conditions, are among those groups of people who are at
higher risk of serious influenza complications (Rothberg et al.,
2008). For example, people with chronic lung disease are
at higher risk of developing severe pneumonia. Because of
severe H7N9 virus infection, the patient had a sequelae of
pulmonary interstitial fibrosis although his recovery from
the infection. The patient developed severe pneumonia with
pH1N1 virus infection, suggesting that a survivor who has
recovered from severe H7N9 virus infection may be at a
higher risk of having severe complications after subsequent
infection with influenza. Therefore, it may be beneficial to
include previous H7N9 virus infected patients in the high-risk
populations recommended to receive human seasonal influenza
vaccination.
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